We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bundle Evaluation in Extra Renal Epuration, Incidence of Thrombosis (BEERT)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01560364
First Posted: March 22, 2012
Last Update Posted: December 2, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University Hospital, Clermont-Ferrand
  Purpose
This is a prospective observational clinical multicentric study in ICU with acute renal failure requiring renal replacement therapy.

Condition Intervention
Adults Receiving Renal Replacement Therapy Other: renal replacement therapy

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Bundle Evaluation in Extra Renal Epuration, Incidence of Thrombosis

Resource links provided by NLM:


Further study details as provided by University Hospital, Clermont-Ferrand:

Primary Outcome Measures:
  • Hemofilter lifetime [ Time Frame: at day 1 ]

Secondary Outcome Measures:
  • Hemofilter clotting risk factors [ Time Frame: at day 1 ]
  • hemofiltration duration [ Time Frame: at day 1 ]
  • down time value [ Time Frame: at day 1 ]

Enrollment: 100
Study Start Date: May 2011
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Hemofilter Other: renal replacement therapy
Prospective observational clinical multicentric study in ICU with acute renal failure requiring renal replacement therapy.

Detailed Description:

Prospective before / after observational clinical multicentric study on ICU acute kidney injury during renal replacement therapy. Evaluation of incidence and exposure to hemofilter clotting.

The after phase will consist in medical measures (help for prescription) and paramedical measures (stop the filtration flow during the patient's mobilization).

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adults receiving renal replacement therapy
Criteria

Inclusion Criteria:

  • Adult (age > 18 years)
  • Renal replacement therapy (continuous veino-veinous hemofiltration or continuous veino-veinous hemodiafiltration)
  • Consent of patients

Exclusion Criteria:

  • Use citrate anticoagulation
  • Age below 18 years
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01560364


Locations
France
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63003
Sponsors and Collaborators
University Hospital, Clermont-Ferrand
Investigators
Principal Investigator: Sébastien PERBET University Hospital, Clermont-Ferrand
  More Information

Responsible Party: University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier: NCT01560364     History of Changes
Other Study ID Numbers: CHU-0106
First Submitted: October 17, 2011
First Posted: March 22, 2012
Last Update Posted: December 2, 2014
Last Verified: November 2014

Keywords provided by University Hospital, Clermont-Ferrand:
Renal replacement therapy
Hemofilter clotting
Clotting risk factor
Hemofilter clotting prevention

Additional relevant MeSH terms:
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases